The Food and Drug Administration (FDA) has approved the inclusion of new data from the ASCENT trial in the prescribing information for Tudorza Pressair (aclidinium bromide inhalation powder ...

TUDORZA PRESSAIR (aclidinium bromide) 400mcg inhalation powder by Forest Laboratories Forest Laboratories and Almirall announced that Tudorza Pressair (aclidinium bromide inhalation powder ...

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung ...

FDA approves Tudorza Pressair for long-term COPD maintenance Tudorza Pressair is now approved for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary ...

AstraZeneca AZN announced positive top-line data from a phase IV study evaluating its marketed drug, Tudorza Pressair (aclidinium bromide 400 mg, twice-daily), for an expanded indication.

(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic ...

NEW YORK & BARCELONA, Spain--(BUSINESS WIRE)-- Forest Laboratories, Inc. (NYS: FRX) and Almirall, S.A. (ALM:MC) announced today that Tudorza™ Pressair™ (aclidinium bromide inhalation powder) 400mcg is ...

Now it's doing the same in the U.S. where some of its Tudorza Pressair inhalers may be defective. According to the most recent FDA Enforcement Report, the U.K. company is voluntarily recalling ...

Drugmaker Forest Laboratories received a subpoena earlier this month from U.S. prosecutors requesting documents relating to its small-selling lung disorder product, the Tudorza Pressair inhaler ...

Almirall SA, the best-performing Spanish pharmaceutical stock, forecast demand for the lung-disease treatment Tudorza Pressair will increase in the U.S. as more managed-care plans cover the drug.

The transaction will grant AstraZeneca the development and commercial rights to Actavis' Tudorza Pressair and Daliresp, two chronic obstructive pulmonary disease medicines. The products generated ...

Tudorza Pressair is an inhalable powder designed to improve breathing in patients with chronic obstructive pulmonary disease. Patients with the disease experience narrowing of the airways to the ...